Abstract:

With the prolonged survival of patients with solid tumors, the incidence of myeloid neoplasms in the patients is gradually increasing after cytotoxic therapy such as chemotherapy and/or radiotherapy. The treatment efficacy and prognosis in the patients are worse than those in patients with primary myeloid neoplasms. Studies have shown that cytotoxic therapy of solid tumors may increase the risk of myeloid neoplasms, and its pathogenesis involves gene mutations, chromosomal abnormalities, and clonal hematopoiesis of indeterminate potential (CHIP). In response to the issue, researchers have proposed individualized treatment strategies, which is selecting appropriate treatment methods based on the molecular biological characteristics of tumors and the overall condition of patients. This article summarizes the incidence, prognosis, pathogenesis, and current treatment methods of myeloid neoplasms post cytotoxic therapy for solid tumors, providing important insights for guiding clinical practice and improving patient prognosis.

Key words: Second primary cance, Clonal hematopoiesis of indeterminate potential, Solid tumors, Epidemiology